NVS Novartis AG

-0.17  -0%
Previous Close 88.32
Open 88.57
Price To Book 2.61
Market Cap 203626500000
Shares 2,310,000,000
Volume 1,933,315
Short Ratio 0.6
Av. Daily Volume 2,633,414

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.
Cosentyx (secukinumab) - SURPASS
Ankylosing spondylitis (AS)
Approval announced April 30, 2018.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
Approval announced May 11, 2018.
Multiple Sclerosis (MS)
Phase 1 initiation of dosing announced January 16, 2018.
Spinal muscular atrophy (SMA) Type 2
FDA Approval announced June 22, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approval announced May 1, 2018.
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3 updated data at ASCO June 4, 2017.
Ribociclib + Letrozole - MONALEESA-2
Breast cancer
CRL issued May 2, 2018.
Biosimilar rituximab
Various blood cancers, rheumatoid arthritis.
Priority review granted February 22, 2017. Approval announced May 26, 2017.
First-line use in patients with ALK+ metastatic NSCLC
Phase 3 trial commenced June 2017.Expected completion 2H 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 trial to be completed 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 2 complete. Regulatory filing due 2018.
Sickle Cell Disease Pain Crises (SCPC)
CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
Acute heart failure
Phase 3 data released June 20, 2017 - primary and key secondary endpoints met. Additional data presented at ARVO conference April 30, 2018.
RTH258 (brolucizumab)
Neovascular AMD
Phase 3 trial to be completed 2H 2019.
Phase 3 data due 2020.
QAW039 (fevipiprant)
Phase 3 trial met primary endpoint - November 8, 2017.
Breast cancer - (pre-menopausal)
Phase 3 data due 2H 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 data presented at ASCO 2018 - PFS 20.5 months v 12.8 months
Kisqali plus fulvestrant: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 data due mid-2019.
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 trial completion due 2020.
Entresto - PARADISE
AMI (acute myocardial infarction)
Approval announced early - August 30, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Phase 3 trial to be completed 2Q 2019.
AIN457 (Cosentyx)
Psoriatic arthritis
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
HR+/HER2- advanced breast cancer
FDA approval announced October 31, 2018.
Rheumatoid Arthritis
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
Inoperable progressive midgut NETs
PDUFA date under priority review May 2019. Exact date not released.
Spinal muscular atrophy (SMA) Type 1
PDUFA date under priority review February 24, 2019.
Graft versus host disease
Pivotal trial initiated 2Q 2018 (Europe). To be completed in 2020.
Spinal muscular atrophy (SMA) Type 1
Phase 2 interim analysis 1H 2018.
Non-alcoholic steatohepatitis (NASH)
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients.
Non-small cell lung cancer
Program discontinued - noted July 18, 2018.
Phase 3 trial met primary endpoint - August 23, 2018. PFS 11 months v 5.7 months for fulvestrant alone.
BYL719 + fulvestrant
HR + Metastatic breast cancer (MBC)
FDA approval announced February 8, 2018.
Phase 3 trial to be initiated 1Q 2019.
Pediatric SMA Types 1, 2, 3
sNDA approval announced November 16, 2018.
Promacta (eltrombopag)
Severe aplastic anemia (SAA)
PDUFA date under priority review set for March 2019. Exact date not noted.
Secondary progressive multiple sclerosis
Phase 3 data due 2H 2019.
BRAFV600 mutant metastatic melanoma
Phase 3 data noted 46% reduction in serious clinical outcomes endpoint.
Entresto - PIONEER
Heart failure
Regulatory filing due 1H 2019.
Sickle cell disease

Latest News

  1. Why Tilray Stock Can Still Set Itself Apart From the Crowd
  2. Alnylam & Medison Partner to Market RNAi Products in Israel
  3. Lilly Stops Lartruvo Promotion as Confirmatory Study Fails
  4. 3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
  5. NVS or AZN: Which Is the Better Value Stock Right Now?
  6. Adamis stock surges on release of EpiPen alternative
  7. Intrexon Signs Licensing Agreement with Next Green Wave
  8. Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off
  9. 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
  10. Here's How The Government Shutdown Will Affect These Medical Stocks
  11. Tilray Shares Rally as Investor Plans Not to Sell Shares
  12. NASH Space in Focus in 2019 as Firms Look to Diversify
  13. Will Tilray’s Dealmaking Lift Tilray Stock in 2019?
  14. Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
  15. Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
  16. Novartis migraine drug not cost effective - U.K. price watchdog
  17. Canopy Growth Moves to Key Resistance
  18. Novartis' Crizanlizumab Gets Breakthrough Therapy Status
  19. Novartis Stock Is Poised to Rise Another 15% From Here
  20. The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase